• There are no suggestions because the search field is empty.

Careers    Developers    Support     日本語

Generalized Anxiety Disorder (GAD)
Trial Solutions

Enhancing study success with advanced clinical research technologies and expert solutions for GAD trials.

DOWNLOAD BROCHURE

Effective solutions for advancing GAD research

Signant Health can apply decades of clinical science and medicine experience, as well as innovative clinical trial technologies within the Signant SmartSignals suite, to help researchers detect safety and efficacy signals while increasing the quality and reliability of data generated.

Generalized anxiety disorder (GAD) is a leading cause of patient suffering and disability around the world, so there is a continued need to develop new, effective treatments and therapeutic options. At Signant, we offer sponsors a team with scientific expertise and global experience, alongside our innovative clinical technology, to help them run successful GAD studies. Leverage our Signant SmartSignals suite to help your adult or pediatric GAD study succeed.

Why Signant Health

  • Simplify Assessments & Adherence for Participants
  • Monitor Endpoint Data in Real-Time
  • Manage Rater Quality to Improve Data Reliability
  • Maximize Signal Detection Opportunities
  • Ensure Participant Comprehension
  • Simplify Assessments & Adherence for Participants

    Simplify Assessments & Adherence for Participants

    Patient-reported and clinician-reported outcome assessments are vital to fully evaluate GAD treatment risk-benefit profiles. Our eCOA solution can be tailored to sites' and patient's needs – guided assessments and built-in edit checks reduce COA errors, while alerts and reminders help improve adherence to medication dosing and assessment schedules.
     
     
     
     
     

  • Monitor Endpoint Data in Real-Time

    Monitor Endpoint Data in Real-Time

    With proprietary algorithms, Signant’s PureSignal Analytics solution evaluates clinical outcome assessment data at all levels in real-time. Expert clinicians analyze outliers, anomalies or discrepancies that could indicate quality risks, and deliver appropriate interventions to safeguard endpoint reliability.
     
     
     
     

  • Manage Rater Quality to Improve Data Reliability

    Manage Rater Quality to Improve Data Reliability

    Train and monitor raters to ensure consistency and accuracy with Rater Training and Qualification as well as Central Review services. Our experts ensure raters adhere to eligibility criteria and score diagnostic/efficacy measures correctly, which can help mitigate excessive placebo response to improve your GAD study’s data reliability. 
     
     
     

  • Maximize Signal Detection Opportunities

    Maximize Signal Detection Opportunities

    Talk through your GAD protocol with our science and medicine experts, who serve as an extension of your study team. We guide the selection and acquisition of endpoints and assessments, advise on inclusion/exclusion criteria, and recommend methods to decrease site and participant burdens.
     
     
     
     
     

  • Ensure Participant Comprehension

    Ensure Participant Comprehension

    Signant’s robust eConsent platform employs multimedia, managed interactions, and content flagging to improve participant comprehension of your protocol requirements while simplifying their consenting experience. Plus, automated version control ensures the presentation of the most recently approved ICD versions, thus preventing a common FDA audit finding.
     
     
     
     

Comprehensive Psychiatry experience

0

STUDIES

0

PATIENTS

0

COUNTRIES

0

SITES

Explore our GAD trial resources
SOLUTION BROCHURE

GAD Trial Solutions Overview

GET INSIGHTS
VIDEO

GAD Trial Solutions

WATCH [2 MIN]
SOLUTION BROCHURE

CNS Research Solutions

 
READ BROCHURE

eClinical solutions for GAD trials

Accelerate your GAD trial success

Discover how Signant's specialized solutions can address unique challenges in your current or upcoming GAD research.

DISCUSS PROTOCOL